22 February 2017
We are proud to have delivered the procurement and supply chain expertise for KalaCORE in Sudan, South Sudan, Ethiopia, India, Bangladesh and Nepal over the past year and are looking forward to continue our work in 2017. IPA supports KalaCORE with procuring and supplying diagnostic equipment, pharmaceuticals for treatment and other essentials.
The Consortium for the Control and Elimination of Visceral Leishmaniasis, known as KalaCORE, is a partnership between the Drugs for Neglected Diseases initiative (DNDi), the London School of Hygiene and Tropical Medicine, Médecins Sans Frontières and Mott MacDonald. The consortium has been appointed by the Department for International Development (DFID) to tackle Visceral Leishmaniasis (VL) in South Asia and East Africa.
KalaCORE which brings together the world’s leading scientific experts and practitioners in VL, delivers the UK aid-funded programme over four years in six countries supporting national efforts and coordinating with national VL control programmes.
Countries in South Asia have almost eliminated the illness. KalaCORE concentrates on supporting these areas with solutions to ongoing problems, such as poor diagnosis, mistreatment, and inefficiency of local institutions.
The disease has reached epidemic proportions in East Africa. The region’s poor national health infrastructures, an HIV epidemic and large displaced populations make it more susceptible to visceral leishmaniasis. Here, KalaCORE focuses on treating patients and improving control methods.
To date, the programme has provided treatment for more than 15,000 patients; information, education and communication interventions have reached more than 3 million people; and more than 10,000 health workers and clinicians have been trained.
To find out more, please visit the website: http://www.kalacore.org